glp-1 reta Retatrutide vs. Tirzepatide: The Next-Gen Showdown GLP-1 Reta 10mg - Peplynx

Ensuring equitable access and strengthening health systems will be essential to prevent widening health disparities.AgendaCo-chairsDr Luz de Regil Director, Department of Nutrition and Food Safety, WHO and Dr Kirsten Bibbins Domingo Editor-in-Chief, JAMAModeratorDr Gaya Manori Gamhewage, Director, Department of Communication, WHOWelcomingDr Luz De Regil Director NFS, WHO and Dr Kirsten Bibbins-Domingo, Editor-in-Chief, JAMAPresentation:WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adultsDr Francesca Celletti, Senior Advisor Obesity, Department of Nutrition and Food Safety, WHO and Dr

A TODAY investigation found that medical scams using AI deepfake videos to sell ineffective products are on the rise

from the University of Mississippi in 1971 and went on to receive his J.D

Although people appear to regain weight rapidly after taking GLP-1 weight-loss drugs this may plateau after time.

One of the most common questions was whether injectables are better than oral options

As of early 2026, several potent single, dual, and triple incretin receptor agonists are in Phase 2/3 trials for MASH including : Survodutide : A dual glucagon (GCGR)/GLP-1 receptor agonist that has shown significant MASH resolution in Phase 2 trials